Table 1.
Demographics of study participants for genome-wide DNA methylation analysis.
Fig 1.
Heatmap visualization of pairwise Spearman correlation coefficients comparing FECD and control corneal endothelium samples with dendrogram to show clustering (Euclidean distance).
Control and FECD samples separate according to disease variable, with the exception of one FECD sample.
Fig 2.
Volcano plot showing statistical significance and fold change effect of individual FECD probes compared to control.
The red line indicates threshold of significance where Q ≤ 0.01.
Fig 3.
Number of differentially methylated probes between FECD and control samples (P < 0.05), grouped by the targeted genomic regions.
Table 2.
Most highly differentially methylated probe sites.
Fig 4.
Gene Ontology (GO) categories most strongly enriched among probes in FECD CE.
Number of represented probes in each category is in parentheses after category name. (A) Gene body DNA hypomethylation, (B) Gene body DNA hypermethylation, (C) Promoter DNA hypomethylation, and (D) Promoter DNA hypermethylation.
Fig 5.
The location of Illumina Infinium HM450 array probes and MethyLight reactions for genes SLC4A11 and GUCY2C.
Table 3.
Demographics of study participants for MethyLight analysis.
Fig 6.
MethyLight analysis for SLC4A11, MIR199B, and GUCY2C in FECD and control endothelial tissues.
Quantitative DNA methylation-sensitive real-time polymerase chain reaction (MethyLight) analyses performed on samples from three control samples and seven FECD samples. MethyLight data are presented as percent of methylated reference (PMR). The table lists the mean PMR values for the control and FECD samples and p-values for each MethyLight assay.